NCT04781244

Brief Summary

This study aimed to study cost-effectiveness of EndWarts® FREEZE for wart treatment, compared to conventional liquid nitrogen cryotherapy

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 12, 2020

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 25, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 4, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 14, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 14, 2022

Completed
Last Updated

March 19, 2024

Status Verified

March 1, 2024

Enrollment Period

1.2 years

First QC Date

February 25, 2021

Last Update Submit

March 18, 2024

Conditions

Keywords

cryotherapy effectwartstreatmentEndWarts FREEZE

Outcome Measures

Primary Outcomes (1)

  • Cost-effectiveness of EndWarts® FREEZE

    Evaluate cost-effectiveness of EndWarts® FREEZE for wart treatment compared with conventional liquid nitrogen therapy. Transportation fee to the hospital, medical and doctor fee are recorded to sum up the costs of treatment at every visit. Every patient is also required to have his/her wart examined by the same physician at each visit with the use of dermoscope to evaluate the result of wart treatment (worse, the same, partial response, complete response). Moreover, wart size is measured for its diameter and height, then photographed at each visit to recorded the change after treatment. Cure rates will be shown according to type of intervention received, with the use of chi-square test.

    12 weeks

Secondary Outcomes (1)

  • Compared Dermatology quality of life index before and after treatment

    12 weeks

Other Outcomes (2)

  • Patient satisfaction of EndWarts® FREEZE

    12 weeks

  • Compared side effect after treatment

    12 weeks

Study Arms (4)

EndWarts® FREEZE in Soft keratin

ACTIVE COMPARATOR

EndWarts® FREEZE were treated to 11 patients with wart at soft keratin

Device: EndWarts® FREEZE

EndWarts® FREEZE in Hard keratin

ACTIVE COMPARATOR

EndWarts® FREEZE were treated to 11 patients with wart at hard keratin

Device: EndWarts® FREEZE

Liquid nitrogen in Soft keratin

ACTIVE COMPARATOR

Liquid nitrogen were treated to 11 patients with wart at soft keratin

Device: Liquid nitrogen

Liquid nitrogen in Hard keratin

ACTIVE COMPARATOR

Liquid nitrogen were treated to 11 patients with wart at hard keratin

Device: Liquid nitrogen

Interventions

EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.

EndWarts® FREEZE in Hard keratinEndWarts® FREEZE in Soft keratin

Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.

Also known as: conventional cryotherapy
Liquid nitrogen in Hard keratinLiquid nitrogen in Soft keratin

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of plantar or common wart at Department of Dermatology, Siriraj hospital

You may not qualify if:

  • Patient with more than 5 warts or wart more than 1 cm in diameter
  • Wart at face, genitalia, scalp, joint
  • Pregnancy or breastfeeding patient
  • Wart with wound/irritation or local infection
  • Diabetes mellitus patients or patients with coagulopathies or cryoglobulinemia
  • Immunocompromised host or on immunosuppressive drug

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Dermatology, Siriraj Hospital Mahidol University

Bangkok Noi, Bangkok, 10700, Thailand

Location

Related Publications (5)

  • Walczuk I, Eertmans F, Rossel B, Cegielska A, Stockfleth E, Antunes A, Adriaens E. Efficacy and Safety of Three Cryotherapy Devices for Wart Treatment: A Randomized, Controlled, Investigator-Blinded, Comparative Study. Dermatol Ther (Heidelb). 2018 Jun;8(2):203-216. doi: 10.1007/s13555-017-0210-5. Epub 2017 Dec 6.

  • Ghadgepatil SS, Gupta S, Sharma YK. Clinicoepidemiological Study of Different Types of Warts. Dermatol Res Pract. 2016;2016:7989817. doi: 10.1155/2016/7989817. Epub 2016 Mar 7.

  • Lipke MM. An armamentarium of wart treatments. Clin Med Res. 2006 Dec;4(4):273-93. doi: 10.3121/cmr.4.4.273.

  • Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014 Oct;171(4):696-712. doi: 10.1111/bjd.13310. Epub 2014 Oct 1. No abstract available.

  • Bruggink SC, Gussekloo J, Berger MY, Zaaijer K, Assendelft WJ, de Waal MW, Bavinck JN, Koes BW, Eekhof JA. Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: randomized controlled trial. CMAJ. 2010 Oct 19;182(15):1624-30. doi: 10.1503/cmaj.092194. Epub 2010 Sep 13.

MeSH Terms

Conditions

Warts

Condition Hierarchy (Ancestors)

Papillomavirus InfectionsDNA Virus InfectionsVirus DiseasesInfectionsSkin Diseases, ViralTumor Virus InfectionsSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Charussri Leeyaphan, Assoc. Prof.

    Department of Dermatology Faculty of Medicine, Siriraj Hospital Mahidol University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 25, 2021

First Posted

March 4, 2021

Study Start

November 12, 2020

Primary Completion

January 14, 2022

Study Completion

January 14, 2022

Last Updated

March 19, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations